Targeted Therapy for Renal Cell Carcinoma

Area of Science:

• Oncology
• Medical Research
• Pharmacology

Background:

• Metastatic renal cell carcinoma (mRCC) presents a significant clinical challenge.
• Targeted therapies offer potential treatment avenues for mRCC.
• Evaluating the efficacy of specific targeted agents is crucial for optimizing patient outcomes.

Purpose of the Study:

• To assess the effectiveness of sunitinib, a tyrosine kinase inhibitor, in patients with metastatic renal cell carcinoma.
• To determine survival outcomes, including median survival and progression-free survival (PFS), in mRCC patients treated with sunitinib.
• To analyze tumor response rates using RECIST criteria.

Main Methods:

• Prospective study conducted over three years (December 2010 - December 2013).
• Included 39 patients with metastatic renal cell carcinoma who underwent radical nephrectomy followed by sunitinib therapy (50 mg OD, 4/2 scheme).
• Utilized RECIST criteria for tumor response evaluation, with regular clinical follow-ups and imaging (X-ray, ultrasound, bone scan, CT).

Main Results:

• Median survival was 28.5 months (CI 9.253-47.7) and PFS was 9.16 months (CI 6.08-12.23).
• Tumor response included stable disease in 6 patients and complete response in 2 patients.
• Clear cell histology predominated (76.9%); lung and bone were the most frequent sites of metastasis (36% and 31%, respectively).

Conclusions:

• Sunitinib treatment in this cohort of metastatic renal cell carcinoma patients yielded outcomes comparable to previously published data.
• The study supports the clinical utility of sunitinib as a targeted therapy option for metastatic renal cell carcinoma.
• Further research may explore optimizing sunitinib regimens or combination therapies for enhanced efficacy.